Medtech Leaders’ Post

Siemens Healthineers has completed the acquisition of Advanced Accelerator Applications Molecular Imaging from Novartis, expanding its production and distribution of PET radiopharmaceuticals. The deal adds 13 European manufacturing sites to Siemens' PETNET Solutions, enhancing delivery capabilities. The PET diagnostics market in the covered regions is expected to triple by 2033

PARTNERSHIP ANNOUNCEMENT: We’re thrilled to announce that Cellipont Bioservices has partnered with Xiogenix to bring the cutting-edge Ares™ X20 fill-and-finish system to our clients! This collaboration marks a significant step forward in enhancing the precision, efficiency, and safety of cell therapy manufacturing processes. Read the full press release here: https://lnkd.in/euEsFEVz #CellTherapy #GeneTherapy #CGT #Innovation #Biotech #CGTCDMO #AdvancedManufacturing #Partnerships #Collaboration

Come see and hear what's happening in New Molecular Modality Drug Discovery!

NervGen’s President & CEO, Mike Kelly, was recently interviewed by Megan Thomas from Drug Discovery World about NervGen’s pipeline and how the approach with its lead molecule, NVG-291, differs from traditional treatments. Read the full Q&A: https://lnkd.in/eTY6y5Vr #SpinalCordInjury #SCI

We are pleased to announce that Vasodynamics has been awarded a significant UK-Taiwan Collaborative R&D Grant from Innovate UK and Taiwan's Department of Industrial Technology, MOEA. This funding will support an international collaboration in partnership with Genenet, Anntond Ind Co Ltd, Pythia Biotech Ltd on groundbreaking R&D efforts to advance organ-on-chip technology for high-efficiency real-time monitoring in microphysiological systems. Our CEO, Ningfeng Fiona Li said: “VasoDynamics are delighted to be part of this Innovation UK Grant consortium to contribute to the innovation and development of this new groundbreaking technology. We are looking forward to taking this opportunity to participate in improving the AI-embedded toxicity screening technology to modernise and accelerate our drug discovery and validation process.”

We’re excited to officially announce our partnership with Cellipont Bioservices, a leading cell therapy CDMO! Together, we’re bringing the cutting-edge Ares™ X20 fill-and-finish system to the forefront of cell therapy manufacturing, enhancing precision, efficiency, and quality.   This collaboration represents a shared commitment to innovation and excellence in biopharmaceutical technology. We’re thrilled to see how this partnership will advance the field and help deliver life-changing therapies to patients worldwide.   Read the full press release here: https://lnkd.in/euEsFEVz #Xiogenix #CellipontBioservices #ARESX20 #CellAndGeneTherapy #InnovationInBiotech #PartnershipForProgress  

very significant in the biosciences and cell and gene therapy space.

Want to know how to get the best possible starting point for groundbreaking medicines? Dive into Evotec's hit identification capabilities in this video! We are a leading expert in hit identification, providing diverse support for screening campaigns through virtual, biochemical, biophysical, cell based, and phenotypic platforms with high-throughput capabilities. Our state-of-the-art platforms, combined with a continuously evolving screening library of over 800,000 small molecules, and our team of experts are here to help you maximize your chances of success. The evidence speaks for itself! So far, we have conducted over 750 successful high-throughput screening projects, with the development of over 1500 assays. For more information on our tailored hit identification campaigns and how these can accelerate your drug discovery, visit: https://hubs.ly/Q02_kcsj0 #researchneverstops #Evotec #HitIdentification

https://lnkd.in/g6VHMu8e (2023 December 9) Commercialization of Space Biomedicine: How SpaceBox Accelerates Drug Screening in Microgravity (AIAA Los Angeles Section)